Intelligent Bio Solutions Files 8-K on Corporate Governance & Voting

TL;DR

Intelligent Bio Solutions filed an 8-K detailing director changes, officer appointments, and shareholder votes.

AI Summary

Intelligent Bio Solutions Inc. filed an 8-K on October 21, 2025, reporting events as of October 16, 2025. The filing covers the departure of directors or officers, election of directors, appointment of officers, compensatory arrangements, submission of matters to a vote of security holders, and financial statements/exhibits. The company, formerly known as GBS Inc., is incorporated in Delaware and its fiscal year ends on June 30.

Why It Matters

This 8-K filing provides crucial updates on the company's leadership, executive compensation, and shareholder voting matters, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — This filing is routine and reports on corporate governance and administrative matters, not immediate financial distress or significant operational changes.

Key Players & Entities

• Intelligent Bio Solutions Inc. (company) — Registrant
• GBS Inc. (company) — Former company name
• Glucose Biosensor Systems (Greater China) Holdings, Inc. (company) — Former company name
• October 16, 2025 (date) — Date of earliest event reported
• October 21, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value INBS The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 70KB
• ex10-1.htm (EX-10.1) — 124KB
• 0001493152-25-018806.txt ( ) — 387KB
• inbs-20251016.xsd (EX-101.SCH) — 3KB
• inbs-20251016_lab.xml (EX-101.LAB) — 33KB
• inbs-20251016_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

02. Departure of

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2025, Intelligent Bio Solutions Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") at which the stockholders of the Company approved an amendment (the "Plan Amendment") to the Company's 2019 Long Term Incentive Plan (the "2019 Plan"). The Plan Amendment increased the aggregate number of shares available for issuance under the 2019 Plan by an additional 495,000 shares (from 1,300,000 shares to 1,795,000 shares). The 2019 Plan and the Plan Amendment are described in further detail in the Company's definitive proxy statement on Schedule 14A for the Annual Meeting (the "Proxy Statement") filed with the Securities and Exchange Commission (the "SEC") on September 19, 2025. A copy of the 2019 Plan, as amended and approved at the Annual Meeting, is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated into this item by reference.

07. Submission

Item 5.07. Submission of Matters to a Vote of Security Holders. The Company's Annual Meeting was held on October 16, 2025, at 3:30 p.m. Eastern Time in a virtual-only format. The number of shares of common stock that voted on matters presented at the Annual Meeting was 4,482,941 shares, representing approximately 49.65% of the 9,028,712 shares of common stock outstanding as of September 11, 2025, the record date for the Annual Meeting. Each director nominee was elected and each other matter submitted to a vote of the Company's stockholders at the Annual Meeting, as described below, was approved by the requisite vote of the Company's stockholders. The final voting results for each of the proposals submitted to a vote of the stockholders of the Company at the Annual Meeting are set forth below. The proposals are described in detail in the Proxy Statement filed with the SEC on September 19, 2025, and are incorporated herein by reference. Proposal 1. The election of four directors, each to serve until the next annual meeting of stockholders, or until each successor is duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Stephen Boyages 1,349,921 503,182 2,629,838 Jonathan Hurd 1,350,740 502,363 2,629,838 Jason Isenberg 1,704,199 148,904 2,629,838 Nicola Fraser 1,706,342 146,761 2,629,838 Proposal 2. To ratify the appointment of UHY LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026. Votes For Votes Against Abstain Broker Non-Votes 4,246,183 227,964 8,794 0 Proposal 3. To approve the amendment of the Company's 2019 Long Term Incentive Plan (the "2019 Plan") to increase the number of shares of common stock authorized for issuance under the 2019 Plan by an additional 495,000, such that the aggregate number of shares subject to the 2019 Plan is increased from 1,300,000 shares to 1,795,000 shares. Votes For Votes Against Absta

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits No. Description 10.1 Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan (as amended October 16, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 21, 2025 INTELLIGENT BIO SOLUTIONS INC. By: /s/ Spiro Sakiris Name: Spiro Sakiris Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR